Achievements
Consortium members have advanced several compounds into clinical studies and have been recognized for their work.
Learn more about our member organizations and their research
Our membership comprises multinational institutions, the pharmaceutical and biotechnology industries, and government agencies
Recent Publications
| The Tuberculosis Drug Accelerator at year 10: what have we learned? Aldridge BB, Barros-Aguirre D, Barry CE 3rd, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu XJ, Cooper CB, Dartois V, Duncan K, Fotouhi N, Gusovsky F, Hipskind PA, Kempf DJ, Lelièvre J, Lenaerts AJ, McNamara CW, Mizrahi V, Nathan C, Olsen DB, Parish T, Petrassi HM, Pym A, Rhee KY, Robertson GT, Rock JM, Rubin EJ, Russell B, Russell DG, Sacchettini JC, Schnappinger D, Schrimpf M, Upton AM, Warner P, Wyatt PG, Yuan Y. Nat Med. 2021 Aug;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2. https://pubmed.ncbi.nlm.nih.gov/34226736/ | Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator Kelsey L. Briggs, Betsy J. Russell, Peter Warner, Ken Duncan, & Steven J. Berthel Drug Discovery Today (2026): 104688. 10.1016/j.drudis.2026.104688 | Strategies for shortening tuberculosis therapy Véronique A. Dartois, Valerie Mizrahi, Radojka M. Savic, Jared A. Silverman, David Hermann & Clifton E. Barry III Nat Med 31, 1765–1775 (2025). https://doi.org/10.1038/s41591-025-03742-3 |